Korean
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Wenzhou Dry Age-related Macular Degeneration (AMD) Progression Study

등록 된 사용자 만 기사를 번역 할 수 있습니다.
로그인 / 가입
링크가 클립 보드에 저장됩니다.
상태모병
스폰서
The Eye Hospital of Wenzhou Medical University

키워드

요약

To evaluate the correlation between macular pigment optical density (MPOD) levels and risk of progression in patients with age-related macular degeneration

기술

Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly.[1] The disease is categorized into early, intermediate, or advanced stages based on the severity of symptoms. The advanced stage, including GA and CNV, involves central region of the retina, which leads to a gradual or rapid loss of photoreceptors and central vision.

The macular pigment (MP) consists of xanthophyll, which is formed from the yellow carotenoid lutein, zeaxanthin, and meso-zeaxanthin.These pigments play an important role in protecting the retina against oxidative stress through different mechanisms[6]. Many studies have shown a various association of AMD and MP.Blue Mountain Eye Study revealed low dietary intake of lutein and zeaxanthin is associated with a higher risk of AMD. However, dry and wet subtypes of AMD may have different etiologies and risk factors. Little is known whether longitudinal study of macular pigment optical density (MPOD) is related to AMD progression.

A comprehensive ophthalmologic examination including fundus photography,OCT and MPOD was performed at baseline, and semiannually thereafter for 3 years. Fundus reflectance (VISUCAM 500, reflectance of a single 460 nm wavelength) was used to measure the MPOD levels. Associated risk factors including body-mass index (BMI), smoking, diet, and cardiovascular diseases were documented. Drusen characteristics (size, type, area), pigmentary abnormalities (increased pigment, depigmentation, geographic atrophy), and presence of abnormalities characteristic of neovascular AMD were graded. For estimations of AMD progression , a 9-step severity scale that combines a 6-step drusen area scale with a 5-step pigmentary abnormality scale is used.

In this study, we are going to investigate a 3-year study of incidence and progression for AMD and associated risk factors, in a population-based cohort of Chinese aged 45 years and older living in the city of Wenzhou.

날짜

마지막 확인: 06/30/2019
처음 제출: 01/29/2018
제출 된 예상 등록: 02/07/2018
처음 게시 됨: 02/14/2018
제출 된 마지막 업데이트: 07/16/2019
마지막 업데이트 게시: 07/17/2019
실제 연구 시작 날짜: 12/31/2017
예상 기본 완료 날짜: 12/30/2020
예상 연구 완료 날짜: 12/30/2023

상태 또는 질병

Macular Pigment Optical Density

단계

-

팔 그룹

개입 / 치료
Progressors
Progressors are those individuals with early or intermediate AMD at baseline who progress to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who progress to advanced AMD in both eyes.
Nonprogressor
Nonprogressors are those individuals with early or intermediate AMD at baseline who do not progressed to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who do not progress to advanced AMD in fellow eye.

자격 기준

공부할 수있는 연령 45 Years 에 45 Years
공부할 수있는 성별All
샘플링 방법Non-Probability Sample
건강한 자원 봉사자를 받아들입니다
기준

Inclusion Criteria:

- subject is diagnosed with either CNV, dry AMD

- 45 years of age or older

- provides signed and dated informed consent

Exclusion Criteria:

- Ocular condition in the study eye which may impact vision and confound study outcomes

- Presence of macular edema like retinal vascular diseases or diabetic retinopathy

- active inflammation ofr infection in the study eye

- high myopia( ≥6D )

결과

1 차 결과 측정

1. Association between changes of macular pigment optical density (MPOD) level and incidence rates of advanced AMD [from baseline to month 36]

Incident advanced AMD was evaluated based on the AMD grade at the end of the clinical trial with follow-up time of 3 years. Progressors were those individuals with early or intermediate AMD at baseline who progressed to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who progressed to advanced AMD in both eyes

2 차 결과 측정

1. Association between age and incident Advanced AMD [baseline]

controlling for age (70 years or older versus younger than 70)

2. Association between gender and incident Advanced AMD [baseline]

3. Association between Baseline AMD grade and incident Advanced AMD [baseline]

Baseline AMD grade was defined as AREDS category 1 in both eyes (essentially free of age-related macular abnormalities), category 2 in the worst eye (mild changes including multiple small drusen, nonextensive intermediate drusen, and/or pigment abnormalities), category 3 in the worst eye (at least one large drusen of at least 125µm diameter, extensive intermediate drusen, and/or noncentral geographic atrophy), category 4 in one eye (advanced AMD, either neovascular or central geographic atrophy, or visual loss due to AMD regardless of phenotype), or category 4 in both eyes.

4. Association between cigarette smoking and incident Advanced AMD [baseline]

cigarette smoking information was acquired by questionaires(never, past, or current) .

5. Association between body mass index (BMI) and incident Advanced AMD [baseline]

BMI was calculated as the weight in kilograms divided by the square of the height in meters ( 25, 25-29.9, and 30 )

페이스 북
페이지에 가입하세요

과학이 뒷받침하는 가장 완벽한 약초 데이터베이스

  • 55 개 언어로 작동
  • 과학이 뒷받침하는 약초 치료제
  • 이미지로 허브 인식
  • 인터랙티브 GPS지도-위치에 허브 태그 지정 (출시 예정)
  • 검색과 관련된 과학 출판물 읽기
  • 효과로 약초 검색
  • 관심사를 정리하고 뉴스 연구, 임상 실험 및 특허를 통해 최신 정보를 확인하세요.

증상이나 질병을 입력하고 도움이 될 수있는 약초에 대해 읽고 약초를 입력하고 사용되는 질병과 증상을 확인합니다.
* 모든 정보는 발표 된 과학 연구를 기반으로합니다.

Google Play badgeApp Store badge